medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2021, Número 1

<< Anterior Siguiente >>

Bol Clin Hosp Infant Edo Son 2021; 38 (1)


¿Ivermectina en la profilaxis y tratamiento del Coronavirus SARS-CoV-2, sí o no?

Anzures-Gutiérrez SA, Reyes-Gómez U, Echeverría-Mayrén C, Reyes-Hernández KL, Pila-Aranda G, Aquino-Villagómez DY, Alonso-Pérez NC, Reyes-Hernández MU, López-Cruz G, Matos-Alviso LJ, Soria-Saavedra FM, Arista-Viveros A

Idioma: Español
Referencias bibliográficas: 53
Paginas: 34-47
Archivo PDF: 179.69 Kb.


RESUMEN

La ivermectina es una lactona macrocíclica semisintética, derivada del actinomiceto Streptomyces avermitilis. Las lactonas macrocíclicas son compuestos precursores, importantes en la química de antibióticos macrólidos, antifúngicos, macrólidos de polieno y algunos antibióticos macrocíclicos contra el cáncer; todos son derivados estructurales de lactonas macrocíclicas. Es un medicamento disponible y asequible que se encuentra en la “Lista de la Organización Mundial de la Salud (OMS) de medicamentos esenciales” y cuenta con un largo historial de seguridad clínica; el medicamento ya está en ensayos clínicos en todo el mundo. Tiene un historial comprobado de seguridad en el uso humano, con el total de dosis distribuidas en los últimos 30 años, equivalente a un tercio de la población mundial actual. En estudios de seguridad, tolerabilidad y farmacocinética, generalmente es bien tolerada, sin indicación de toxicidad asociada al SNC para dosis de hasta 10 veces la dosis más alta. A gran escala, las intervenciones realizadas en Perú, Brasil, Paraguay y la India indican que luego de la distribución masiva del fármaco entre la población, las tasas de incidencia de la enfermedad cayeron de forma importante. Existen diversos grupos a nivel internacional a favor del fármaco, los cuales recomiendan su uso y realizan estudios al respecto, como la FLCCC, Tratamientotemprano.org, entre otros organismos. A nivel mundial, hay más de 50 estudios publicados y otros en proceso respecto a su empleo y aplicación, los NIH han retirado la restricción para su uso y la OMS está realizando una revisión exhaustiva, considerando que hay resultados prometedores.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bertram GK. Basic & Clinical Pharmacology. (14 ed.) USA: McGraw Hill Education; 2018.

  2. Davida EG, Ehrin JA, April WA. Principios de Farmacología, bases fisiopatológicas del tratamiento. (4ª ed). Barcelona, España: Wolters Kluwer; 2017.

  3. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020 Sep; 73(9): 593-602. doi: 10.1038/s41429-020-0336-z. Epub: 2020 Jun 12. PMID: 32533071; PMCID: PMC7290143.

  4. Rang PH, Ritter MJ, Flower JR, Henderson G. Ring y Dale, Farmacología. (8ª ed.). España: ELSEVIER; 2016.

  5. Brunton LL, Hilal-Dandan R, Knollmann CB. Goodman & Gilman. Las bases farmacológicas de la terapéutica. (13ª edición). Ciudad de México: McGraw Hill Education; 2019.

  6. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, Sah R, Bonilla-Aldana DK, Rodríguez- Morales AJ, Leblebicioglu H. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID- 19. Ann Clin Microbiol Antimicrob. 2020 May 30; 19(1): 23. doi: 10.1186/s12941-020-00368-w. PMID: 32473642; PMCID: PMC7261036.

  7. WHO | WHO Model Lists of Essential Medicines [Internet]. Disponible en: https://www.who.int/medicines/ publications/essentialmedicines/en/

  8. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002 Oct; 42(10): 1122-33. doi: 10.1177/009127002401382731. PMID: 12362927.

  9. Navarro M, Camprubí D, Requena-Méndez A, Buonfrate D, Giorli G, Kamgno J, Et al. A safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020 Apr 1; 75(4): 827-834. doi: 10.1093/jac/dkz524. PMID: 31960060.

  10. Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020 Apr 22; 35: 100684. doi: 10.1016/j.nmni.2020.100684. PMID: 32322397; PMCID: PMC7175902.

  11. Jean SS, Hsueh PR. Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther. 2020 Sep; 18(9): 843-847. doi:10.1080/14787210.2020.1771181. Epub: 2020 Jun1. PMID: 32419524; PMCID: PMC7441793.

  12. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun; 178: 104787. Epub: 2020 Apr 3. PMID: 32251768; PMCID: PMC7129059. https:// doi.org/10.1016/j.antiviral.2020.104787

  13. Rizzo E. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul; 393(7): 1153-1156. doi: 10.1007/s00210-020- 01902-5. Epub: 2020 May 27. PMID: 32462282; PMCID: PMC7251046.

  14. Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020 Apr 21; 50(SI-1): 611- 619. doi: 10.3906/sag-2004-145. PMID: 32293834; PMCID: PMC7195979.

  15. Hamed MA. An overview on COVID-19: reality and expectation. Bull Natl Res Cent. 2020; 44(1): 86. doi: 10.1186/s42269-020-00341-9. Epub: 2020 Jun1. PMID: 32514228; PMCID: PMC7266424.

  16. Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? J Am Acad Dermatol. 2020 Jun; 82(6): e221. doi: 10.1016/j. jaad.2020.04.017. Epub: 2020 Apr 10. PMID: 32283237; PMCID: PMC7146719.

  17. Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernández-Montero A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo- controlled, randomized clinical trial. EClinicalMedicine. 2021 Jan 19: 100720. doi: 10.1016/j. eclinm.2020.100720. Epub ahead of print. PMID: 33495752; PMCID: PMC7816625.

  18. Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther. 2020 Oct; 108(4): 762-765. doi: 10.1002/cpt.1889. Epub: 2020 Jun 7. PMID: 32378737; PMCID: PMC7267287.

  19. Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, et al. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin Pharmacol Ther. 2020 Oct; 108(4): 775-790. doi: 10.1002/ cpt.1909. Epub: 2020 Jun 14. PMID: 32438446; PMCID: PMC7280633.

  20. Portmann BA, Bryce A, Alfonso AR. Propiedades antivirales y antiinflamatorias de ivermectina y su potencial uso en COVID-19. Arch Bronconeumol.2020. Disponible en: https://doi.org/10.1016/j.arbres.2020.06.011

  21. Shouman W. Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient with COVID-19. Clinical Trials.gov. 2020. NCT04422561

  22. Carvallo H. Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of COVID-19 (IVERCAR). Disponible en: www.clinicaltrials.gov NCT04425850

  23. Behera P, Patro BK, Singh AK, Chandanshive PD, S.R RK, Pradhan SK, et al. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study. Disponible en: https://www.medrxiv.org/content/10. 1101/2020.10.29.20222661v1.

  24. Kory P, Meduri UG, Iglesias J, Varon J, Berkowitz K, Kornfeld H, et al. “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” OSF Preprints. November 13. doi:10.31219/osf.io/wx3zn.

  25. Connel A. An Old Drug Tackles New Tricks: Ivermectin Treatment in Three Brazilain Towns; 2020. Disponible en: https://www.trialsitenews.com/anold- drug-tackles-new-tricks-ivermectin-treatmentin- three-brazilian-towns/

  26. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020.

  27. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The ICON Study. Chest. 2020 Oct 13; 159(1):85-92. doi: 10.1016/j. chest.2020.10.009. Epub ahead of print. PMID: 33065103; PMCID: PMC7550891.

  28. Khan MSI, Khan MSI, Debnath CR, Nath PN, Mahtab MA, Nabeka H, Matsuda S, Akbar SMF. Ivermectin treatment may improve the prognosis of patients with COVID-19. Archivos de Bronconeumología; 2020. doi: https://doi.org/10.1016/j.arbres. 2020.08.007

  29. Gorial FI, Mashhadani S, Sayaly HM, et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). medRxiv; preprint. doi: https://doi.org/10.1101/2020.07.07.20145979.

  30. Carvallo HE, Hirsch RR, Farinella ME. Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin, and Aspirin. medRxiv. 2020. Disponible en: https://doi. org/10.1101/2020.09.10.20191619

  31. Horowitz RI, Freeman PR. (2020). Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. Medical hypotheses. 143: 109851. Advance online publication. Disponible en: https://doi. org/10.1016/j.mehy.2020.109851

  32. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020; 23: 462-469. doi: 10.18433/ jpps31457. PMID: 33227231.

  33. Morgenstern J, Redondo J, De León A, et al. The use of compassionate ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of covid-19 at the medical center bournigal and the medical center Punta Cana, rescue group, dominican republic, from may 1 to august 10, 2020. medRxiv; preprint. doi: https://doi. org/10.1101/2020.10.29.20222505

  34. Nasir A, Muhammad IG Mukarram MA, Muhammad YP, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting (11/18/2020). Disponible en: SSRN: https://ssrn.com/abstract=3734478 or http:// dx.doi.org/10.2139/ssrn.3734478

  35. Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso D, et al. Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial. SSRN; 2020.

  36. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2020 Dec 2; 103: 214-6. doi: 10.1016/j.ijid.2020.11.191. Epub ahead of print. PMID: 33278625; PMCID: PMC7709596.

  37. Alam MT, Murshed R, Gomes PF, Masud Z, Saber S, Chaklader MA, et al. Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka –An Observational Study. European Journal of Medical and Health Sciences. 15 Dec 2020. doi:10.24018/ ejmed.2020.2.6.599, https://ejmed.org/index.php/ejmed/ article/view/599.

  38. Elgazzar A, Basma H, Shaimaa Abo Y, Basma H, Mohy H, Hany M. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. Research Square. 2020. doi: 10.21203/ rs.3.rs-100956/v1 https://www.researchsquare.com/ article/rs-100956/v3

  39. Niaee MS, Nematollah G, Peyman N, Abbas A, Leila Z, Amir J, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Research Square. 2020. doi: https://doi.org/10.21203/rs.3.rs-109670/ v1

  40. Procter BC, Ross C, Pickard V, Smith E, Hanson C, et al. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicina. 2020; 21 (4): 611-614. doi:10.31083/j. rcm.2020.04.260

  41. Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Int J Antimicrob Agents. 2021 Jan; 57(1): 106248. doi: 10.1016/j.ijantimicag. 2020.106248. Epub: 2020 Nov 28. PMID: 33259913; PMCID: PMC7698683.

  42. Espitia HG, Munguía L, Díaz CD, López ER, Jiménez PF. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. Biomedical Research. 2020; 31, Issue 5. ISSN: 0970-938X (Print) | 0976-1683 (Electronic) https://www.biomedres. info/biomedical-research/effects-of-ivermectinazithromycincholecalciferol- combined-therapy- on-covid19-infected-patients-a-proof-of-concept- study-14435.html

  43. Hill A. On behalr of the International Ivermectin Project Team. Preliminary meta-analysis of randomized trials of ivermectina to treat SARS-CoV-2 infection. Research Squiare. PrePrint. Disponible en: https://www.researchsquare.com/article/rs-148845/ v1

  44. Tess L. Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. Disponible en: https://covid19.cdmx.gob.mx/storage/app/media/ Articulos/Ivermectin%20reducesthe%20risk%20ofdeath% 20from%20COVID-19.pdf

  45. Chamie J. Front Line COVID-19 Critical Care Alliance (FLCCC). Prevention & Treatment Protocols for COVID-19. Epidemiologic Analyses on COVID-19 and Ivermectin. Disponible en: https:// covid19criticalcare.com/i-mask-prophylaxis-treatment- protocol/epidemiologic-analyses-on-covid19- and-ivermectin/

  46. U. S. National Library of Medicine. ClinicalTrials. gov. Disponible en: https://clinicaltrials.gov.

  47. Organización Panamericana de la Salud. Recomendación sobre el uso de ivermectina para el tratamiento de la COVID-19. 22 de junio del 2020. Disponible en: https://iris.paho.org/bitstream/handle/ 10665.2/52379/OPSIMSCDECOVID-19200033_ spa.pdf?sequence=1&isAllowed=y

  48. The Pan American Health Organization (PAHO). Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 17 February 2021. PAHO/IMS/EIH/COVID-19/21-0003. www.paho.org/coronavirus.

  49. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Disponible en: https://www.covid19treatmentguidelines.nih.gov/. Accessed [23/02/2021].

  50. Gobierno de la Ciudad de México. Secretaría de Salud. ADIP. Covid19. Evidencia científica sobre el uso de ivermectina para Covid-19 Publicado el 23 Enero 2021. Disponible en: https://covid19.cdmx.gob. mx/comunicacion/nota/evidencia-cientifica- sobre-el-uso-de-ivermectina-para-covid-19

  51. Instituto Mexicano del Seguro Social. Dirección de Prestaciones Médicas. Análisis breve de la evidencia y recomendaciones sobre el uso de Ivermectina en COVID-19; 2021. Disponible en: https://covid19. cdmx.gob.mx/storage/app/media/Articulos/revision- de-ivermectina-corregida13ene20.pdf

  52. Olavarria A. Estrategia de Tratamiento Temprano. Una mirada distinta para enfrentar el Covid-19. Estrategia de Tratamiento Temprano Covid-19” con Ivermectina. Disponible en: https://tratamientotemprano. org/ivermectina/

  53. Van KG. Organización Mundial de la Salud (OMS). Conferencia de Prensa. Ivermectina: OMS espera los resultados de su propia evaluación. Disponible en: https://www.fundacionfemeba.org.ar/blog/farmacologia- 7/post/ivermectina-oms-espera-los-resultados- de-su-propia-evaluacion-en-6-semanas-48846. http://bit.ly/IVER_OMS17




2020     |     www.medigraphic.com